SEARCH

SEARCH BY CITATION

REFERENCES

  • Brenu EW, van Driel ML, Staines DR, Ashton KJ, Ramos SB, Keane J, Klimas NG, Marshall-Gradisnik SM. 2011. Immunological abnormalities as potential biomarkers in chronic fatigue syndrome/myalgic encephalomyelitis. J Transl Med 9:8190.
  • Briggs NC, Levine PH. 1994. A comparative review of systemic and neurological symptomatology in 12 outbreaks collectively described as chronic fatigue syndrome, epidemic neuromyasthenia, and myalgic encephalomyelitis. Clin Infect Dis 18:S32S42.
  • Broderick G, Fuite J, Kreitz A, Vernon SD, Klimas N, Fletcher MA. 2010. A formal analysis of cytokine networks in chronic fatigue syndrome. Brain Behav Immun 24:12091217.
  • Bryceson AD. 1976. Clinical pathology of the Jarisch–Herxheimer reaction. J Infect Dis 133:696704.
  • Buchwald D, Ashley RL, Pearlman T, Kith P, Komaroff AL. 1996. Viral serologies in patients with chronic fatigue and chronic fatigue syndrome. J Med Virol 50:2530.
  • Butler LM, Jeffery HC, Wheat RL, Rae PC, Townsend K, Alkharsah KR, Schulz TF, Nash GB, Blackbourn DJ. 2011. Kaposi's sarcoma-associated herpesvirus infection of endothelial cells inhibits neutrophil recruitment through an interleukin-6-dependent mechanism: A new paradigm for viral immune evasion. J Virol 85:73217332.
  • Fluge Ø, Bruland O, Risa K, Storstein A, Kristoffersen EK, Storstein A, Kristoffersen EK, Sapkota D, Næss H, Dahl O, Nyland H, Mella O. 2011. Benefit from B-lymphocyte depletion using the anti-CD20 antibody rituximab in chronic fatigue syndrome. A double-blind and placebo-controlled study. PLoS ONE 6:e26358.
  • Fukuda K, Straus SE, Hickie I, Sharpe MC, Dobbins JG, Komaroff A. 1994. The chronic fatigue syndrome: A comprehensive approach to its definition and study. International Chronic Fatigue Syndrome Study Group. Ann Intern Med 121:953959.
  • Gentile S, Delaroziere JC, Favre F, Sambuc R, San Marco JL. 2003. Validation of the French 'multidimensional fatigue inventory' (MFI 20). Eur J Cancer Care (Engl) 12:5864.
  • Hickie I, Davenport T, Wakefield D, Vollmer-Conna U, Cameron B, Vernon SD, Reeves WC, Lloyd A. 2006. Post-infective and chronic fatigue syndromes precipitated by viral and non-viral pathogens: Prospective cohort study. BMJ 333:575581.
  • Janelle ME, Flamand L. 2006. Phenotypic alterations and survival of monocytes following infection by human herpesvirus-6. Arch Virol 151:16031614.
  • Katz BZ, Shiraishi Y, Mears CJ, Binns HJ, Taylor R. 2009. Chronic fatigue syndrome after infectious mononucleosis in adolescents. Pediatrics 124:189193.
  • Kerr JR, Bracewell J, Laing I, Mattey DL, Bernstein RM, Bruce IN, Tyrrell DA. 2002. Chronic fatigue syndrome and arthralgia following parvovirus B19 infection. J Rheumatol 29:595602.
  • Klimas NG, Broderick G, Fletcher MA. 2012. Biomarkers for chronic fatigue. Brain Behav Immun 26:12021210.
  • Kogelnik AM, Loomis K, Hoegh-Petersen M, Rosso F, Hischier C, Montoya JG. 2006. Use of valganciclovir in patients with elevated antibody titers against Human Herpesvirus-6 (HHV-6) and Epstein–Barr Virus (EBV) who were experiencing central nervous system dysfunction including long-standing fatigue. J Clin Virol 37:S33S38.
  • Komaroff AL. 2006. Is human herpesvirus-6 a trigger for chronic fatigue syndrome? J Clin Virol 37:S39S46.
  • Komaroff AL, Cho TA. 2011. Role of infection and neurologic dysfunction in chronic fatigue syndrome. Semin Neurol 31:325337.
  • Kondo K, Kondo T, Shimada K, Amo K, Miyagawa H, Yamanishi K. 2002. Strong interaction between human herpesvirus 6 and peripheral blood monocytes/macrophages during acute infection. J Med Virol 67:364369.
  • Lerner AM, Beqaj SH, Deeter RG, Dworkin HJ, Zervos M, Chang CH, Fitzgerald JT, Goldstein J, O'Neill W. 2002. A six-month trial of valacyclovir in the Epstein–Barr virus subset of chronic fatigue syndrome: Improvement in left ventricular function. Drugs Today 38:549561.
  • Lerner AM, Beqaj SH, Deeter RG, Fitzgerald JT. 2007. Valacyclovir treatment in Epstein–Barr virus subset chronic fatigue syndrome: Thirty-six months follow-up. In Vivo 21:707713.
  • Lerner AM, Beqaj SH, Fitzgerald JT, Gill K, Gill C, Edington J. 2010. Subset-directed antiviral treatment of 142 herpesvirus patients with chronic fatigue syndrome. Virus Adapt Treat 2:4757.
  • Levine PH. 1994. Summary and perspective: Epidemiology of chronic fatigue syndrome. Clin Infect Dis 18:S57S60.
  • Lin JM, Brimmer DJ, Maloney EM, Nyarko E, Belue R, Reeves WC. 2009. Further validation of the multidimensional fatigue inventory in a US adult population sample. Popul Health Metr 7:1830.
  • Liu GN, Shi HZ, Xie ZH, Shen HH, Huang HQ, Deng JM, Liang QL, Wu YB. 2009. Epithelial neutrophil-activating peptide-78 recruits neutrophils into pleural effusion. Eur Respir J 34:184190.
  • Montoya JG. 2007. Improving the tools in the fight against cytomegalovirus or strengthening David to defeat Goliath. Curr Opin Infect Dis 20:397398.
  • Patnaik M, Komaroff AL, Conley E, Ojo-Amaize EA, Peter JB. 1995. Prevalence of IgM antibodies to human herpesvirus 6 early antigen (p41/38) in patients with chronic fatigue syndrome. J Infect Dis 172:13641367.
  • Razonable RR. 2011. Antiviral drugs for viruses other than human immunodeficiency virus. Mayo Clin Proc 86:10091026.
  • Reeves WC, Wagner D, Nisenbaum R, Jones JF, Gurbaxani B, Solomon L, Papanicolaou DA, Unger ER, Vernon SD, Heim C. 2005. Chronic fatique syndrome—A clinically emprical approach to its definition and study. BMC Med 3:1928.
  • Savard M, Belanger C, Tardif M, Gourde P, Flamand L, Gosselin J. 2000. Infection of primary human monocytes by Epstein–Barr virus. J Virol 74:26122619.
  • Straus SE, Tosato G, Armstrong G, Lawley T, Preble OT, Henle W, Davey R, Pearson G, Epstein J, Brus I, Blaese RM. 1985. Persisting illness and fatigue in adults with evidence of Epstein–Barr virus infection. Ann Intern Med 102:716.
  • Straus SE, Dale JK, Tobi M, Lawley T, Preble O, Blaese RM, Hallahan C, Henle W. 1988. Acyclovir treatment of the chronic fatigue syndrome. Lack of efficacy in a placebo-controlled trial. New Engl J Med 319:16921698.
  • Tobi M, Morag A, Ravid Z, Chowers I, Feldman-Weiss V, Michaeli Y, Ben-Chetrit E, Shalit M, Knobler H. 1982. Prolonged atypical illness associated with serological evidence of persistent Epstein–Barr virus infection. Lancet 1:6164.
  • Tugizov S, Herrera R, Veluppillai P, Greenspan J, Greenspan D, Palefsky JM. 2007. Epstein–Barr virus (EBV)-infected monocytes facilitate dissemination of EBV within the oral mucosal epithelium. J Virol 81:54845496.
  • Walling DM, Ray AJ, Nichols JE, Flaitz CM, Nichols CM. 2007. Epstein–Barr virus infection of Langerhans cell precursors as a mechanism of oral epithelial entry, persistence, and reactivation. J Virol 81:72497268.